Shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) have been given an average rating of “Hold” by the five analysts that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $39.25.
CALT has been the topic of several recent analyst reports. HC Wainwright restated a “neutral” rating and set a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Lifesci Capital cut shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 28th. Citigroup reiterated a “neutral” rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Jefferies Financial Group restated a “hold” rating and issued a $39.00 target price (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $40.00 price target (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th.
Get Our Latest Research Report on Calliditas Therapeutics AB (publ)
Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ) Trading Up 1.7 %
CALT opened at $40.41 on Wednesday. Calliditas Therapeutics AB has a fifty-two week low of $15.25 and a fifty-two week high of $41.90. The firm has a market capitalization of $1.20 billion, a PE ratio of -21.84 and a beta of 1.77. The company has a debt-to-equity ratio of 8.46, a current ratio of 2.69 and a quick ratio of 2.62. The company’s 50-day moving average is $38.95 and its 200 day moving average is $28.72.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The firm had revenue of $52.36 million during the quarter, compared to the consensus estimate of $42.89 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. During the same period in the prior year, the business posted ($0.33) earnings per share. As a group, research analysts predict that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.
Calliditas Therapeutics AB (publ) Company Profile
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
Further Reading
- Five stocks we like better than Calliditas Therapeutics AB (publ)
- How to Evaluate a Stock Before Buying
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Industrial Products Stocks Investing
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.